Literature DB >> 17764615

The role of the p38 pathway in adaptive immunity.

Ryan Cook1, Chia-Cheng Wu, Young Jun Kang, Jiahuai Han.   

Abstract

Since its discovery in 1993, the mitogen-activated protein (MAP) kinase p38 has attracted much attention for its role in a wide range of cellular processes, many of which involve the immune system. Although p38 has been heavily implicated in the function of all type immune cells, research has tended focus on its role in innate immunity. In this review we attempt to highlight some of the major discoveries that have been made regarding p38's role in adaptive immunity, and also to discuss the possible future implications of these discoveries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17764615

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  18 in total

1.  Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease.

Authors:  G Docena; L Rovedatti; L Kruidenier; A Fanning; N A B Leakey; C H Knowles; K Lee; F Shanahan; K Nally; P G McLean; A Di Sabatino; T T MacDonald
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

2.  Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis.

Authors:  Liu Zhi-Chun; Zhou Qiao-Ling; Liu Zhi-Qin; Li Xiao-Zhao; Zuo Xiao-xia; Tang Rong
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

3.  Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice.

Authors:  Elaine V Lourenço; Claudio Procaccini; Francesca Ferrera; Noriko Iikuni; Ram P Singh; Gilberto Filaci; Giuseppe Matarese; Fu-Dong Shi; Ernest Brahn; Bevra H Hahn; Antonio La Cava
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK.

Authors:  Tracy Dodd; Rashmi Jadhav; Luke Wiggins; James Stewart; Erika Smith; James C Russell; Petra Rocic
Journal:  J Mol Cell Cardiol       Date:  2011-08-22       Impact factor: 5.000

5.  MLK4 has negative effect on TLR4 signaling.

Authors:  Alim Seit-Nebi; Wei Cheng; Hong Xu; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2011-05-23       Impact factor: 11.530

6.  Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats.

Authors:  Yanyan Sun; Hongping Chen; Shuainan Ma; Lixin Liang; Yi Zheng; Xiao Guo; Mingfei Wang; Wei Wang; Guozhong Li; Di Zhong
Journal:  Neurochem Res       Date:  2015-05-22       Impact factor: 3.996

7.  Translational control of NKT cell cytokine production by p38 MAPK.

Authors:  Viswas K Nagaleekar; Guadalupe Sabio; Idil Aktan; Alan Chant; Isaac W Howe; Tina M Thornton; Patrick J Benoit; Roger J Davis; Mercedes Rincon; Jonathan E Boyson
Journal:  J Immunol       Date:  2011-03-02       Impact factor: 5.422

8.  A p38 MAPK-MEF2C pathway regulates B-cell proliferation.

Authors:  Dustin Khiem; Jason G Cyster; John J Schwarz; Brian L Black
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

Review 9.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

10.  FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice.

Authors:  Takashi Nishimura; Akira Andoh; Atsushi Nishida; Makoto Shioya; Yuhsuke Koizumi; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.